Boundless Bio
PublicBoundless Bio is now publicly traded
The data on this page reflects Boundless Bio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Mar 28, 2024
Last Round
Series C
May 16, 2023
Total Funding Raised
$377M
Company Overview
Boundless Bio is a clinical-stage oncology company focused on developing innovative therapies that target extrachromosomal DNA to treat patients with oncogene amplified tumors.
Sector
Biotech
AI Layer
Non-AI
Keywords
Boundless Bio Comparables
Compare Boundless Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Illudent Therapeutics | 68% |
Boundless Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Mar 28, 2024 | ||||
| Series C | May 16, 2023 | ||||
| Grant | Jun 16, 2022 | ||||
| Series B | Apr 28, 2021 | ||||
| Series A | Sep 19, 2019 |
Key People
Founding team and executive leadership
Boundless Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B, Series C |
| National Cancer Institute | Grant |
| RA Capital Management | Series B, Series C |
| Cancer Grand Challenges | Grant |
| Vertex Ventures HC | Series B, Series C |
| Guggenheim Securities | IPO |
| Heartland Healthcare Capital | Series C |
Boundless Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access